Real-world use of fidaxomicin in a large UK tertiary hospital: How effective is it for treating recurrent disease?

Tools

Enoch, D. A., Santos, R., Phillips, C. J., Micallef, C. ORCID: https://orcid.org/0000-0002-4513-8199, Murphy, M. E., Aliyu, S. H., Massey, D. and Brown, N. M. (2018) Real-world use of fidaxomicin in a large UK tertiary hospital: How effective is it for treating recurrent disease? Journal of Hospital Infection, 100 (2). pp. 142-146. ISSN 0195-6701

Full text not available from this repository. (Request a copy)

Abstract

All courses of fidaxomicin use in the study hospital were reviewed. It was used for first recurrence (six times), second recurrence (eight times) and one case of third recurrence. One patients received fidaxomicin as first-line treatment. Eight patients initially responded to therapy; of these, three patients were asymptomatic at 90 days, three patients remained asymptomatic at 30 days, and two patients had recurrences five and nine days after stopping therapy. Four patients failed to respond; of these, two patients required faecal transplantation and one patient required a colectomy. Two patients deteriorated and two patients died. Fidaxomicin was well tolerated. These findings suggest that the utility of fidaxomicin at this stage of infection is unclear.

Item Type:	Article
Additional Information:	Funding Information: DAE has received funding to attend conferences from MSD, Gilead and Astellas. MM has received funding to attend one conference from Astellas. CM has received funding to attend conferences from Astellas, Gilead, Pfizer and Novartis; has received educational grants from Pfizer and Novartis; has attended a Pfizer Advisory Board Meeting; and has consulted for Astellas. SHA has served on UK advisory boards for Gilead and MSD, and has received sponsorship to attend international meetings from Schering-Plough, Gilead and Wyeth. All other authors declare no conflicts of interest. Publisher Copyright: © 2018 The Healthcare Infection Society
Uncontrolled Keywords:	clostridium difficile,fidaxomicin,recurrence,microbiology (medical),infectious diseases,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2726
Faculty \ School:	Faculty of Science > School of Pharmacy
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	18 Aug 2022 08:30
Last Modified:	22 Oct 2022 07:55
URI:	https://ueaeprints.uea.ac.uk/id/eprint/87408
DOI:	10.1016/j.jhin.2018.05.001

Actions (login required)

View Item